Cargando…

Immunotoxins: From Design to Clinical Application

Detalles Bibliográficos
Autores principales:	Kreitman, Robert J., Pastan, Ira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615697/ https://www.ncbi.nlm.nih.gov/pubmed/34827694 http://dx.doi.org/10.3390/biom11111696

Ejemplares similares

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model
por: Pak, Youngshang, et al.
Publicado: (2014)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
por: Mazor, Ronit, et al.
Publicado: (2020)

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
por: Dieffenbach, Michael, et al.
Publicado: (2020)

Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs
por: Berger, Edward A., et al.
Publicado: (2010)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
por: Leshem, Yasmin, et al.
Publicado: (2019)

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
por: Vallera, Daniel A., et al.
Publicado: (2018)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
por: Kaplan, Gilad, et al.
Publicado: (2016)

Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway
por: Liu, Xiu-Fen, et al.
Publicado: (2017)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
por: Leshem, Yasmin, et al.
Publicado: (2018)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022)

Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study
por: Wang, Guannan, et al.
Publicado: (2022)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
por: Bera, Tapan K.
Publicado: (2020)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2019)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics
por: Weigel, Kelsey J., et al.
Publicado: (2015)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

From Immunotoxins to Suicide Toxin Delivery Approaches: Is There a Clinical Opportunity?
por: Ardini, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nr0fmp6cor8iaif4p0d67brd9j